阿昔替尼 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "阿昔替尼" in Chinese language version.

refsWebsite

Global rank Chinese rank

12web.archive.org

1^st place

7nih.gov

4^th place

5^th place

6doi.org

2^nd place

23^rd place

1medscape.com

719^th place

889^th place

1archive.today

14^th place

18^th place

1ascopubs.org

low place

1drugs.com

399^th place

208^th place

1medpagetoday.com

9,274^th place

low place

1europa.eu

68^th place

209^th place

1medicines.org.uk

3,823^rd place

3,456^th place

1tga.gov.au

3,984^th place

1,603^rd place

1reuters.com

49^th place

81^st place

1genengnews.com

low place

1onclive.com

low place

1fda.gov

447^th place

581^st place

1spandidos-publications.com

low place

archive.today

Rini, B; Rixe, O; Bukowski, R; Michaelson, MD; Wilding, G; Hudes, G; Bolte, O; Steinfeldt, H; Reich, SD. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings. June 2005, 23 (16S): 4509. （原始内容存档于2014-01-26）.

ascopubs.org

meeting.ascopubs.org

Rini, B; Rixe, O; Bukowski, R; Michaelson, MD; Wilding, G; Hudes, G; Bolte, O; Steinfeldt, H; Reich, SD. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings. June 2005, 23 (16S): 4509. （原始内容存档于2014-01-26）.

doi.org

Wilmes, LJ; Pallavicini, MG; Fleming, LM; Gibbs, J; Wang, D; Li, KL; Partridge, SC; Henry, RG; Shalinsky, DR. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magnetic Resonance Imaging. April 2007, 25 (3): 319–27. PMID 17371720. doi:10.1016/j.mri.2006.09.041.
Rugo, HS; Herbst, RS; Liu, G; Park, JW; Kies, MS; Steinfeldt, HM; Pithavala, YK; Reich, SD; Freddo, JL. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of Clinical Oncology. August 2005, 23 (24): 5474–83. PMID 16027439. doi:10.1200/JCO.2005.04.192.
Spano, JP; Chodkiewicz, C; Maurel, J; Wong, R; Wasan, H; Barone, C; Létourneau, R; Bajetta, E; Pithavala, Y. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. June 2008, 371 (9630): 2101–2108. PMID 18514303. doi:10.1016/S0140-6736(08)60661-3.
Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A. Repasky; Jeffrey Chen; Peter Wells; Ciarán N. Cronin; Michele McTigue; Olli Kallioniemi. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015, 519 (7541): 102–105. PMID 25686603. doi:10.1038/nature14119.
Escudier, B; Gore, M. Axitinib for the Management of Metastatic Renal Cell Carcinoma. Drugs in R&D. 2011, 11 (2): 113–126. PMC 3585900 . PMID 21679004. doi:10.2165/11591240-000000000-00000.
Zhang Y. Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.. J Mol Med Rep. Jan 2014, 9 (1): 83–90 [2019-09-23]. PMID 24213221. doi:10.3892/mmr.2013.1781. （原始内容存档于2018-09-20）.

drugs.com

FDA Approves Inlyta for Advanced Renal Cell Carcinoma. Drugs.com. January 27, 2012 [2019-09-23]. （原始内容存档于2016-09-18）.

europa.eu

ema.europa.eu

Inlyta : EPAR - Product Information (PDF). European Medicines Agency. Pfizer Ltd. 17 December 2013 [25 January 2014]. （原始内容存档 (PDF)于2018-07-05）.

fda.gov

accessdata.fda.gov

FDA Prescribing Information (PDF). 30 Jan 2012 [2019-09-23]. （原始内容存档 (PDF)于2017-02-25）.

genengnews.com

Pfizer's Phase III Trial in mRCC Turns Up Positive Results. 19 Nov 2010 [2019-09-23]. （原始内容存档于2018-02-20）.

medicines.org.uk

Inlyta 1 mg 3mg, 5 mg & 7mg film-coated tablets - Summary of Product Characteristics (SPC). electronic Medicines Compendium. Pfizer Limited. 5 December 2013 [25 January 2014]. （原始内容存档于2014-02-22）.

medpagetoday.com

John Fauber; Elbert Chu. The Slippery Slope: Is a Surrogate Endpoint Evidence of Efficacy?. Milwaukee Journal Sentinel/MedPage Today. Oct 27, 2014 [2019-09-23]. （原始内容存档于2017-04-29）.

medscape.com

reference.medscape.com

Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. [25 January 2014]. （原始内容存档于2018-07-05）.

nih.gov

ncbi.nlm.nih.gov

Wilmes, LJ; Pallavicini, MG; Fleming, LM; Gibbs, J; Wang, D; Li, KL; Partridge, SC; Henry, RG; Shalinsky, DR. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magnetic Resonance Imaging. April 2007, 25 (3): 319–27. PMID 17371720. doi:10.1016/j.mri.2006.09.041.
Rugo, HS; Herbst, RS; Liu, G; Park, JW; Kies, MS; Steinfeldt, HM; Pithavala, YK; Reich, SD; Freddo, JL. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of Clinical Oncology. August 2005, 23 (24): 5474–83. PMID 16027439. doi:10.1200/JCO.2005.04.192.
Spano, JP; Chodkiewicz, C; Maurel, J; Wong, R; Wasan, H; Barone, C; Létourneau, R; Bajetta, E; Pithavala, Y. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. June 2008, 371 (9630): 2101–2108. PMID 18514303. doi:10.1016/S0140-6736(08)60661-3.
Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A. Repasky; Jeffrey Chen; Peter Wells; Ciarán N. Cronin; Michele McTigue; Olli Kallioniemi. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature. 2015, 519 (7541): 102–105. PMID 25686603. doi:10.1038/nature14119.
Escudier, B; Gore, M. Axitinib for the Management of Metastatic Renal Cell Carcinoma. Drugs in R&D. 2011, 11 (2): 113–126. PMC 3585900 . PMID 21679004. doi:10.2165/11591240-000000000-00000.
Zhang Y. Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.. J Mol Med Rep. Jan 2014, 9 (1): 83–90 [2019-09-23]. PMID 24213221. doi:10.3892/mmr.2013.1781. （原始内容存档于2018-09-20）.

dailymed.nlm.nih.gov

INLYTA (axitinib) tablet, film coated [Pfizer Laboratories Div Pfizer Inc]. DailyMed. Pfizer Laboratories Div Pfizer Inc. September 2013 [25 January 2014]. （原始内容存档于2019-11-27）.

onclive.com

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma. 7 Dec 2011 [2019-09-23]. （原始内容存档于2018-04-05）.

reuters.com

Pfizer pancreatic cancer drug fails, trial halted. Reuters. January 30, 2009 [2019-09-23]. （原始内容存档于2009-02-14）.

spandidos-publications.com

Zhang Y. Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.. J Mol Med Rep. Jan 2014, 9 (1): 83–90 [2019-09-23]. PMID 24213221. doi:10.3892/mmr.2013.1781. （原始内容存档于2018-09-20）.

tga.gov.au

ebs.tga.gov.au

PRODUCT INFORMATION INLYTA (axitinib) (PDF). TGA eBusiness Services. Pfizer Australia Pty Ltd. 5 July 2013 [25 January 2014]. （原始内容存档于2019-03-29）.

web.archive.org

Inlyta (axitinib) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. [25 January 2014]. （原始内容存档于2018-07-05）.
FDA Approves Inlyta for Advanced Renal Cell Carcinoma. Drugs.com. January 27, 2012 [2019-09-23]. （原始内容存档于2016-09-18）.
John Fauber; Elbert Chu. The Slippery Slope: Is a Surrogate Endpoint Evidence of Efficacy?. Milwaukee Journal Sentinel/MedPage Today. Oct 27, 2014 [2019-09-23]. （原始内容存档于2017-04-29）.
INLYTA (axitinib) tablet, film coated [Pfizer Laboratories Div Pfizer Inc]. DailyMed. Pfizer Laboratories Div Pfizer Inc. September 2013 [25 January 2014]. （原始内容存档于2019-11-27）.
Inlyta : EPAR - Product Information (PDF). European Medicines Agency. Pfizer Ltd. 17 December 2013 [25 January 2014]. （原始内容存档 (PDF)于2018-07-05）.
Inlyta 1 mg 3mg, 5 mg & 7mg film-coated tablets - Summary of Product Characteristics (SPC). electronic Medicines Compendium. Pfizer Limited. 5 December 2013 [25 January 2014]. （原始内容存档于2014-02-22）.
PRODUCT INFORMATION INLYTA (axitinib) (PDF). TGA eBusiness Services. Pfizer Australia Pty Ltd. 5 July 2013 [25 January 2014]. （原始内容存档于2019-03-29）.
Pfizer pancreatic cancer drug fails, trial halted. Reuters. January 30, 2009 [2019-09-23]. （原始内容存档于2009-02-14）.
Pfizer's Phase III Trial in mRCC Turns Up Positive Results. 19 Nov 2010 [2019-09-23]. （原始内容存档于2018-02-20）.
ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma. 7 Dec 2011 [2019-09-23]. （原始内容存档于2018-04-05）.
FDA Prescribing Information (PDF). 30 Jan 2012 [2019-09-23]. （原始内容存档 (PDF)于2017-02-25）.
Zhang Y. Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.. J Mol Med Rep. Jan 2014, 9 (1): 83–90 [2019-09-23]. PMID 24213221. doi:10.3892/mmr.2013.1781. （原始内容存档于2018-09-20）.